What chronic pain opioid prescribing guidelines exist?

Key guidelines include: CDC Clinical Practice Guideline for Prescribing Opioids (2022) — recommends risk assessment tools, PDMP check, UDS, and naloxone co-prescription for all long-term opioid patients. VA/DoD Clinical Practice Guideline for Opioid Therapy for Chronic Pain (2022) — recommends ORT as one of multiple risk assessment tools. ASAM recommendations on pain and addiction. All guidelines emphasize individualized risk-benefit assessment and proportionate monitoring based on risk level.

What are prescription drug monitoring programs (PDMPs)?

PDMPs are state-run electronic databases that track controlled substance prescriptions. All 50 US states and Washington DC now have PDMPs. Prescribers are required (in most states) to check the PDMP before prescribing controlled substances including opioids. PDMPs identify multiple-prescriber patterns, early refills, and concurrent prescriptions for benzodiazepines or other controlled substances. They are a critical complement to ORT assessment — the ORT identifies risk factors from history while PDMP identifies current prescribing patterns.

When should urine drug screening be done for opioid patients?

Urine drug screening (UDS) is recommended: (1) baseline before initiating opioid therapy, (2) periodically during treatment — frequency based on ORT risk level: annually for low risk, quarterly for moderate risk, monthly for high risk. UDS detects the prescribed opioid (confirms appropriate use), illicit substances (heroin, cocaine, methamphetamine, fentanyl), unprescribed controlled substances, and alcohol metabolites. Unexpected UDS findings should be discussed with the patient and interpreted in clinical context before changing management.

What are naloxone co-prescription guidelines?

CDC (2022) recommends naloxone co-prescription for all patients prescribed opioids above 50 MME/day, patients with any substance use history, and patients combining opioids with benzodiazepines. VA/DoD guidelines also recommend naloxone for all opioid patients. Naloxone is available as nasal spray (Narcan) and auto-injector (EVZIO). Patient and family education on recognition of overdose signs and naloxone administration is essential. Many states have standing orders allowing pharmacists to dispense naloxone without a specific prescription.

What is the ORT for chronic pain risk assessment versus clinical judgment?

The ORT provides a structured, documented risk stratification that supplements clinical judgment — it does not replace it. Clinical judgment incorporates the full picture: pain severity, functional impairment, response to non-opioid treatments, patient goals, social support, and the therapeutic relationship. The ORT's value is in preventing clinician overconfidence in 'low-risk appearing' patients (who may have hidden risk factors) and in systematically documenting risk assessment for regulatory and medicolegal purposes. Use ORT as one input into a comprehensive clinical assessment, not as a sole decision-making algorithm.

What is opioid misuse risk stratification in primary care?

Risk stratification for opioid therapy in primary care uses multiple tools: ORT for pre-opioid risk scoring, PDMP check at every prescription, urine drug screening at baseline and periodically, and clinical monitoring for aberrant behaviors. Risk stratification determines monitoring intensity (standard vs enhanced vs intensive) and should be reassessed whenever significant changes occur (new psychiatric diagnosis, substance use incident, new controlled substance from another provider). Patients in the high-risk tier may warrant referral to addiction medicine or pain specialist co-management.

Online Medical Tools — Opioid Risk Tool

Printed on 9/3/2026

For informational purposes only. This is not medical advice.

Mental Health

Opioid Risk Tool

The Opioid Risk Tool (ORT) is a brief risk-screening instrument used to estimate potential opioid misuse risk in chronic pain treatment contexts. It incorporates family/personal substance history, age range, trauma history, and psychological comorbidity profile.

Formula: ORT total is the sum of weighted risk factors, with common risk bands: 0-3 low, 4-7 moderate, >=8 high.

Family history of substance abuse

Personal history of substance abuse

Age 16-45 years

History of preadolescent sexual abuse

Psychological disease (ADD/OCD/bipolar/schizophrenia/depression)

Save your results with a free account

Keep a history of calculations, favorite tools, and access your dashboard anytime.

Create free account Sign in

How It Works

Score 5 Risk Items Using Gender-Specific Weights

The ORT assigns different point values to each risk item depending on the patient's sex, reflecting different epidemiological patterns of substance use and trauma history. The five items and their gender-specific weights are: (1) Family history of substance abuse — alcohol (M=3, F=1), illegal drugs (M=3, F=2), prescription drugs (M=4, F=4); (2) Personal history of substance abuse — alcohol (M=3, F=1), illegal drugs (M=4, F=5), prescription drugs (M=4, F=4); (3) Age 16-45 (M=1, F=1); (4) History of preadolescent sexual abuse (M=0, F=3); (5) Psychological disease — ADHD, OCD, bipolar, schizophrenia (M=2, F=2), depression (M=1, F=1). Use the gender-specific weights precisely — using male weights for female patients or vice versa is a scoring error.

Sum All Weighted Items to Produce Total Score (0-26)

After assigning gender-specific weights to each applicable risk factor, sum all points to produce a total score. The maximum possible score is 26 for males and 26 for females (different items reach maximum differently). Each risk factor should be verified through clinical history — ask specifically about family and personal substance use history, age, trauma history, and psychiatric diagnoses. The ORT should be administered and documented before initiating long-term opioid therapy.

Interpret Risk Band and Implement Appropriate Monitoring Strategy

Low risk (0-3): 3.1% predicted aberrant drug behavior — standard monitoring (periodic urine drug screening, PDMP check, annual reassessment). Moderate risk (4-7): 28.1% predicted aberrant behavior — enhanced monitoring (more frequent UDS, smaller prescription quantities, more frequent visits). High risk (8 and above): 91.9% predicted aberrant behavior — intensive monitoring (frequent UDS, very small supplies, monthly visits, risk counseling, consider pain specialist co-management). High ORT does NOT preclude opioid therapy — it mandates proportionately intensive monitoring and risk mitigation.

Who Uses the Opioid Risk Tool

Pre-Opioid Prescription Risk Stratification in Chronic Pain

Pain Medicine Specialists

Pain medicine practices use the ORT as a standard pre-opioid assessment tool to classify risk stratification and determine monitoring intensity. The ORT score directly informs the monitoring plan documented in opioid treatment agreements and clinical records.

Primary Care Opioid Initiation Decision Support

General Practitioners

Primary care physicians use the ORT to structure opioid initiation conversations, identify high-risk patients requiring specialist co-management, and document clinical reasoning for prescribing decisions in the context of state PDMP requirements and regulatory oversight.

Addiction Risk Counseling Before Long-Term Opioids

Primary Care Providers

The ORT provides a structured framework for discussing individual addiction risk factors with patients before starting opioids. Transparent discussion of risk scores builds therapeutic alliance and helps patients participate in designing appropriate monitoring plans.

Prescribing Decision Documentation for State PDMP

Prescribers

All US states have prescription drug monitoring programs (PDMPs) requiring prescriber checks before controlled substance prescribing. ORT documentation supports the clinical reasoning required for PDMP registration and demonstrates appropriate risk assessment in regulatory reviews.

Identifying Patients Needing Enhanced Monitoring on Opioids

Pain Specialists

For patients already on long-term opioid therapy, the ORT reassessment identifies those who have developed new risk factors or whose risk profile warrants escalation of monitoring intensity including urine drug screening frequency and prescription supply limitations.

Pro Tips

ORT Must Be Completed BEFORE Initiating Long-Term Opioid Therapy

The ORT is a pre-opioid initiation tool. Its clinical value is in informing the monitoring plan and risk-benefit discussion before the first prescription, not after aberrant behaviors have already occurred. The CDC 2022 Clinical Practice Guideline for Prescribing Opioids explicitly recommends risk assessment using validated tools like the ORT before initiating long-term opioid therapy for chronic pain.

High ORT Does NOT Mean Deny Opioids — It Means Intensify Monitoring

The ORT was designed to stratify risk and guide monitoring intensity, not to provide binary prescribing decisions. Denying opioid therapy to high-ORT patients in uncontrolled pain is not the appropriate clinical response. Rather, high ORT (8+) signals the need for more frequent clinic visits, smaller prescription supplies, routine urine drug screening, PDMP checks, and possibly pain specialist co-management. Risk stratification enables individualized, proportionate monitoring.

Use Gender-Specific Weights — This Is a Major Scoring Error If Ignored

The ORT's most important technical feature is that item weights differ by patient sex. The preadolescent sexual abuse item scores 0 for males and 3 for females. Personal history of illegal drug abuse scores 4 for males but 5 for females. Family history of alcohol abuse scores 3 for males but 1 for females. These gender differences reflect real epidemiological patterns and substantially affect total scores. Always verify the patient's sex before applying weights — using the wrong column is a significant scoring error.

PDMP Check Is Mandatory for All Controlled Substance Prescriptions

All 50 US states have prescription drug monitoring programs (PDMPs) that track controlled substance prescriptions. Before prescribing opioids, checking the state PDMP to identify multiple-prescriber patterns, early refills, and concurrent controlled substance prescriptions from other providers is mandatory in most states. The ORT complements PDMP checking by adding historical risk factor information that the PDMP alone does not capture (family history, trauma history, psychiatric comorbidity).

Urine Drug Screening Should Be Performed at Baseline and Periodically for All Long-Term Opioid Patients

Urine drug screening (UDS) is recommended at baseline before starting opioid therapy and at periodic intervals during treatment (quarterly to annually depending on risk level) for all patients on long-term opioid therapy. UDS results should be interpreted in clinical context — unexpected findings warrant discussion with the patient, not automatic discharge. Low ORT patients may need annual UDS; high ORT patients may need monthly UDS. Document UDS results and clinical interpretation in the medical record.

Naloxone Co-Prescription Is Recommended for Patients at Elevated Overdose Risk

Naloxone (Narcan) co-prescription is recommended by CDC and VA/DoD guidelines for all patients on opioids above 50 morphine milligram equivalents (MME) per day, all patients with high ORT scores, patients with any substance use history, and patients who combine opioids with benzodiazepines or sedative-hypnotics. Naloxone availability at home allows family members to reverse accidental or intentional overdose. Most state PDMPs now facilitate naloxone prescribing documentation.

Opioid Treatment Agreements Are Recommended But Evidence for Reducing Aberrant Behavior Is Mixed

Opioid treatment agreements (patient-provider agreements or 'pain contracts') document the expectations, risks, monitoring requirements, and consequences of opioid therapy. Many pain medicine and primary care guidelines recommend them as part of opioid prescribing. However, the evidence that they reduce aberrant drug behavior or improve outcomes is mixed, and they should be viewed as part of a comprehensive monitoring strategy rather than a standalone intervention. They do serve an important documentation and shared-decision-making function.

ORT Performance May Be Lower in Primary Care Than in Specialty Pain Clinics

The ORT was developed and validated in a specialty pain clinic population where patients were being evaluated for opioid therapy. Multiple subsequent validation studies in primary care settings have shown lower predictive validity (lower AUC) in primary care populations. This reflects differences in patient population, prescribing context, and the base rate of aberrant drug behaviors. In primary care settings, the ORT should be used as one component of risk assessment alongside PDMP checking, UDS, and clinical judgment rather than as a definitive risk calculator.

Common Questions About Your Results

No. A high ORT score (8+) means the patient has risk factors associated with a 91.9% predicted rate of aberrant drug behavior — it does not mean opioids should be denied. Patients with high ORT and legitimate chronic pain have the right to receive appropriate pain treatment. A high ORT score mandates proportionately intensive monitoring: frequent clinic visits (monthly), smaller prescription supplies, routine urine drug screening, PDMP monitoring at every prescription, naloxone co-prescription, and consideration of pain specialist co-management. Balancing pain treatment with addiction risk management is the clinical goal.

Aberrant drug-related behaviors range in severity from minor to major. Less serious: early refill requests, reports of lost/stolen prescriptions, requesting specific opioids by name. More serious: urine drug screen showing absent prescribed opioid (possible diversion), urine drug screen showing unprescribed opioids or illicit substances, multiple prescriptions from multiple providers, dose escalation without authorization. The most serious: prescription forgery, selling prescribed opioids, injection of oral formulations. Response should be proportionate to behavior severity — most require enhanced monitoring rather than immediate termination of opioid therapy.

The ORT and DIRE (Diagnosis, Intractability, Risk, Efficacy) score are both used for opioid risk assessment in chronic pain, but they differ in approach. The ORT focuses exclusively on risk factors for substance misuse and scores risk stratification. The DIRE evaluates both risk factors AND predicted efficacy of opioid therapy — a higher DIRE score (out of 21) suggests a 'good candidate' for opioid therapy. The ORT is more widely used in the US and is endorsed by more guidelines. Some practices use both tools for a more comprehensive assessment.

Epidemiological research showed that preadolescent sexual abuse is a significant risk factor for substance use disorders in women but not statistically significant in men — hence the gender-specific weight of 3 for females and 0 for males. This reflects different trauma-substance use associations by sex in the original pain clinic population. Similarly, personal history of illegal drug use was weighted higher for females because this behavior has stronger predictive value for opioid aberrant behavior in women in this population. These gender differences reflect real clinical epidemiology but also reflect the limitations of the original validation sample.

Evidence-Based Methodology

ORT published by Webster and Webster (Pain Med 2005) from 185 chronic pain patients. High risk (8+): 91.9% aberrant drug behavior; low risk (0-3): 3.1%. Internal consistency alpha 0.86. Multiple validation studies in specialty pain populations; variable performance in primary care settings. CDC Opioid Prescribing Guidelines (2022) recommend risk assessment tools before initiating opioids. VA/DoD Clinical Practice Guideline for Opioid Therapy (2022) recommends ORT as one of multiple risk assessment tools. PDMPs mandate by state health departments (all US states now have PDMPs).

Clinical Content Trust

Last reviewed:: April 21, 2026
Guideline version:: General evidence framework v2026.04
Source set version:: Primary-source set v1

How to Interpret Your Result

Higher ORT scores indicate higher potential opioid misuse risk and support stronger safety planning and follow-up.

When to Use This Tool

Use during chronic pain assessment when opioid therapy is being considered or reviewed.

Limitations

ORT is a screening aid and does not diagnose substance use disorder; predictive performance varies by population and setting.

For related assessments, see CAGE, AUDIT and PHQ-9.

Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.

Changelog

April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.

Related Tools

Mental Health

CAGE

Quick four-question alcohol screening using the CAGE questionnaire. A score of 2 or more suggests possible alcohol problems. For comprehensive screening, use [AUDIT](/tools/audit).

Open Mental Health

AUDIT

Screen for hazardous and harmful alcohol use with the 10-question AUDIT. Scores range from 0 to 40 across four risk zones. For quick screening use [CAGE](/tools/cage).

Open Mental Health

PHQ-9

Free PHQ-9 depression screening questionnaire. Take the Patient Health Questionnaire-9 to assess depression severity with instant scoring and interpretation. Also screen for anxiety with [GAD-7](/tools/gad7).

Open Mental Health

GAD-7

Free GAD-7 anxiety screening questionnaire. Take the Generalized Anxiety Disorder 7-item scale to assess anxiety severity with instant scoring and interpretation. Also screen for depression with [PHQ-9](/tools/phq9).

Open

Frequently Asked Questions

The ORT is a 5-item clinician-administered risk assessment tool developed to predict the probability of aberrant drug-related behaviors in chronic pain patients before initiating long-term opioid therapy. Items include family history of substance abuse, personal history of substance abuse, age 16-45, history of preadolescent sexual abuse, and psychological disease. Items are scored with gender-specific weights, and the total (0-26) classifies patients as low (0-3), moderate (4-7), or high risk (8+).

Score each of 5 items using gender-specific weights (different for males vs females — see scoring sheet). Sum all applicable items. Use male column for male patients and female column for female patients — this is critical as weights differ substantially. Key differences: preadolescent sexual abuse = 0 for males, 3 for females; personal illegal drug history = 4 for males, 5 for females. Total risk bands: 0-3 = low, 4-7 = moderate, 8+ = high.

An ORT score of 8 or above indicates high risk — associated with a 91.9% predicted rate of aberrant drug-related behaviors in the original validation (versus 3.1% for low risk and 28.1% for moderate risk). High ORT does NOT mean opioids should be denied. It means intensive monitoring is required: monthly visits, small prescription supplies, routine urine drug screening, PDMP checks, naloxone co-prescription, and possibly pain specialist co-management.

The ORT is administered before initiating long-term opioid therapy for chronic pain. It is one component of comprehensive pre-opioid assessment, which also includes PDMP check, urine drug screening, detailed pain assessment, and informed consent discussion. The ORT score determines monitoring intensity tier: low risk = standard monitoring; moderate risk = enhanced monitoring; high risk = intensive monitoring. Document the ORT score, risk tier, and monitoring plan in the medical record.

ORT (0-26) stratifies risk for opioid aberrant behaviors based on patient risk factors — it predicts who is at risk but not who will benefit. DIRE (0-21) evaluates both risk and predicted efficacy of opioid therapy for each patient — higher DIRE scores indicate both lower risk and higher expected benefit. The ORT is more widely endorsed in US clinical guidelines. Some practices use both for a more complete assessment.

In the original Webster and Webster (2005) validation from 185 chronic pain patients: high risk (8+) predicted 91.9% aberrant drug behavior rate; moderate risk (4-7) predicted 28.1%; low risk (0-3) predicted 3.1%. Internal consistency alpha 0.86. Multiple subsequent validation studies in primary care settings have shown lower predictive validity (AUC 0.60-0.74) than the original specialty pain clinic data, suggesting the ORT performs best in contexts similar to its development setting.

Online Medical Tools — Opioid Risk Tool

Opioid Risk Tool

How It Works

Score 5 Risk Items Using Gender-Specific Weights

Sum All Weighted Items to Produce Total Score (0-26)

Interpret Risk Band and Implement Appropriate Monitoring Strategy

Who Uses the Opioid Risk Tool

Pre-Opioid Prescription Risk Stratification in Chronic Pain

Primary Care Opioid Initiation Decision Support

Addiction Risk Counseling Before Long-Term Opioids

Prescribing Decision Documentation for State PDMP

Identifying Patients Needing Enhanced Monitoring on Opioids

Pro Tips

ORT Must Be Completed BEFORE Initiating Long-Term Opioid Therapy

High ORT Does NOT Mean Deny Opioids — It Means Intensify Monitoring

Use Gender-Specific Weights — This Is a Major Scoring Error If Ignored

PDMP Check Is Mandatory for All Controlled Substance Prescriptions

Urine Drug Screening Should Be Performed at Baseline and Periodically for All Long-Term Opioid Patients

Naloxone Co-Prescription Is Recommended for Patients at Elevated Overdose Risk

Opioid Treatment Agreements Are Recommended But Evidence for Reducing Aberrant Behavior Is Mixed

ORT Performance May Be Lower in Primary Care Than in Specialty Pain Clinics

Common Questions About Your Results

Evidence-Based Methodology

Clinical Content Trust

How to Interpret Your Result

When to Use This Tool

Limitations

Changelog

Related Tools

CAGE

AUDIT

PHQ-9

GAD-7

Further Reading

Mental Health Screening Guide: Depression, Anxiety, Substance Use, and Cognitive Assessment

Frequently Asked Questions